Diagnosing cancers of unknown primaries
Friday, 27 February, 2009
A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.
The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.
The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.
Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.
For more information, see the March/April issue of Australian Life Scientist.
Breakthrough drug prevents long COVID symptoms in mice
Mice treated with the antiviral compound were protected from long-term brain and lung dysfunction...
Antibiotics hinder vaccine response in infants
Infants who received antibiotics in the first few weeks of life had significantly lower levels of...
Colossal announces 'de-extinction' of the dire wolf
Colossal Biosciences has announced what it describes as the rebirth of the dire wolf, which would...
